Tags

Type your tag names separated by a space and hit enter

Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
Anticancer Res. 1994 Sep-Oct; 14(5A):1703-9.AR

Abstract

Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay. The greatest level of overexpression of the marker was observed in patients with ovarian cancer. Using a cutoff of 4 fmol/mg creatinine, UGP was overexpressed in samples from 2% of normal premenopausal women, 15% of normal postmenopausal women, 5% of women with benign gynecologic disease, and 59% of women with ovarian cancer. UGP expression was independent of the histologic type of ovarian cancer. The expression of UGP and CA 125 were not correlated and use of the two markers in tandem increased the sensitivity of detection of disease by greater than 20% over that which was observed using each marker individually. UGP levels were correlated with clinical status, and doubled in value in 67% of patients with progressive disease, and were halved in 93% of patients who were in remission at the time of the study.

Authors+Show Affiliations

Ciba-Corning Diagnostics Corp., Alameda, CA 94502.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

7847804

Citation

Walker, R, et al. "Urinary Gonadotropin Peptide (UGP) as a Marker of Gynecologic Malignancies." Anticancer Research, vol. 14, no. 5A, 1994, pp. 1703-9.
Walker R, Crebbin V, Stern J, et al. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. Anticancer Res. 1994;14(5A):1703-9.
Walker, R., Crebbin, V., Stern, J., Scudder, S., & Schwartz, P. (1994). Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. Anticancer Research, 14(5A), 1703-9.
Walker R, et al. Urinary Gonadotropin Peptide (UGP) as a Marker of Gynecologic Malignancies. Anticancer Res. 1994 Sep-Oct;14(5A):1703-9. PubMed PMID: 7847804.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. AU - Walker,R, AU - Crebbin,V, AU - Stern,J, AU - Scudder,S, AU - Schwartz,P, PY - 1994/9/1/pubmed PY - 1994/9/1/medline PY - 1994/9/1/entrez SP - 1703 EP - 9 JF - Anticancer research JO - Anticancer Res VL - 14 IS - 5A N2 - Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay. The greatest level of overexpression of the marker was observed in patients with ovarian cancer. Using a cutoff of 4 fmol/mg creatinine, UGP was overexpressed in samples from 2% of normal premenopausal women, 15% of normal postmenopausal women, 5% of women with benign gynecologic disease, and 59% of women with ovarian cancer. UGP expression was independent of the histologic type of ovarian cancer. The expression of UGP and CA 125 were not correlated and use of the two markers in tandem increased the sensitivity of detection of disease by greater than 20% over that which was observed using each marker individually. UGP levels were correlated with clinical status, and doubled in value in 67% of patients with progressive disease, and were halved in 93% of patients who were in remission at the time of the study. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/7847804/Urinary_gonadotropin_peptide__UGP__as_a_marker_of_gynecologic_malignancies_ L2 - https://antibodies.cancer.gov/detail/CPTC-MUC16-1 DB - PRIME DP - Unbound Medicine ER -